Sincere Capital
Sincere Capital is a venture capital firm based in Shanghai, China, founded in 2015 by experienced investment specialists. The firm focuses on early and late-stage investments across various sectors, including hard and core technology, intelligent manufacturing, entertainment, healthcare, clean technology, and financial technology. It has a particular interest in technology innovations such as the Internet of Things (IoT), where it seeks opportunities in semiconductors, new materials, sensors, and high-end equipment. In the biotechnology sector, Sincere Capital targets innovative medicine, medical equipment, and precision medicine. The firm aims to exit its investments primarily through mergers and acquisitions or initial public offerings. Additionally, it is actively involved in state-owned enterprise reforms, contributing to the modernization and efficiency of these entities.
13 past transactions
Spectral Domain Technology
Series A in 2024
Spectral Domain Technology is a provider of 5G low-orbit broadband terminals, supplying operators, industrial Internet companies, satellite Internet, and government and enterprise customers with ocean communication needs.
Laser Link
Series A in 2023
Laser Link is a company specializing in laser communication technologies, focusing on the development of precision optical-mechanical products for various applications. Its innovations encompass inter-satellite communication systems, including co-orbit and off-orbit laser communication terminals and components. Additionally, Laser Link produces precision optical-mechanical payload machines designed for use in spaceborne, airborne, and ground communication environments. By offering advanced products and components, the company aims to enhance communication capabilities across satellite and aircraft platforms.
Zenosic
Series A in 2023
Zenosic focuses in the design and R&D of high-performance network chips, along with offering leading chip products for cloud service providers, equipment makers, operators, and diverse industries.
Cullgen
Series C in 2023
Cullgen Inc. is a biopharmaceutical company based in San Diego, California, founded in 2018. The company specializes in the development of innovative small molecule therapeutics aimed at treating diseases that currently lack effective therapeutic options, including cancer, inflammatory, and autoimmune diseases. Utilizing its proprietary uSMITE™ platform, Cullgen employs targeted protein degradation technology to selectively degrade disease-causing proteins, even those previously deemed undruggable. This approach enables the creation of first-in-class new chemical entities, providing scientists with novel methodologies for drug discovery and potentially transforming treatment paradigms for difficult-to-treat conditions.
Base Therapeutics
Series A in 2023
Base Therapeutics is a biotechnology company focused on developing cell and gene editing technologies aimed at treating cancerous diseases. Its core innovation includes a natural killer cell genetic engineering platform, along with various cell therapy products specifically designed for the treatment of lung cancer, liver cancer, glioma, and other hematological tumors. By enhancing the safety and effectiveness of clinical applications of gene editing, Base Therapeutics aims to provide healthcare professionals with advanced therapeutic options for patients suffering from these challenging conditions.
GalaxySpace
Series D in 2022
GalaxySpace is a satellite manufacturer based in Haidian, China, founded in 2016. The company specializes in developing and building a low Earth orbit (LEO) broadband satellite constellation and a 5G communication network. GalaxySpace offers various satellite applications, including monitoring systems for airports, parking, and oil reserves, as well as land assessment services. Their product range includes communication payloads, phased array antennas, power management systems, solar panels, and core platform components. Additionally, the company provides one-stop artificial intelligence satellite launch services, facilitating convenient communication and information access for clients while reducing network costs.
Bichen Pharmaceutical
Series B in 2022
Bichen Pharmaceutical is a small-molecule tumor-targeted drug developer for the treatment of various malignant tumors and brain metastases.
Yoguang Technology
Seed Round in 2021
Seetrum is an electronics manufacturing firm that provides advanced spectroscopy chips, AI algorithms, and smart perception solutions.
Hongxin Gases
Seed Round in 2021
Hongxin Gases is a electronic bulk gas solution platform that focuses on providing professional and high-quality electronic gas overall solutions for semiconductor industry manufacturing companies.
GeneMind Biosciences
Series B in 2020
GeneMind Biosciences Company Limited, founded in 2012 and based in Shenzhen, China, specializes in the development and manufacturing of medical devices, particularly focusing on third-generation genome sequencing technology. This advanced technology enables noninvasive detection, disease diagnosis, and personalized treatment options. GeneMind aims to enhance gene sequencing solutions for clinicians and researchers, positioning its gene sequencer as a key asset in the field. The company's commitment to innovation is driven by ongoing research efforts to overcome challenges in gene sequencing, reflecting its dedication to advancing healthcare through improved diagnostic capabilities.
Mabwell Biotech
Series A in 2020
Mabwell Biotech is a Chinese innovative biopharmaceutical company based in Shanghai Zhangjiang Hi-Tech Park. Since its establishment in 2017, it has absorbed and newly established nine biopharmaceutical R&D and production enterprises. At present, the company focuses on the development and manufacturing of macromolecular drugs such as therapeutic monoclonal antibodies and long-acting recombinant proteins. There are more than thirty varieties of drugs at different stages of development covering tumor, autoimmunity, anti-infection and ophthalmic diseases. Among them, six of them have entered the clinical stage, and three of them are in Phase III clinical trials.
Nation Rfid
Angel Round in 2018
Nation RFID is a developer of radio frequency identification (RFID) chips, specializing in tag chips, reader chips, and system integration software. The company offers comprehensive solutions tailored for diverse sectors, including intelligent transportation, logistics, military, retail, and communications. As the only enterprise in China holding a dual-chip patent for RFID technology, Nation RFID is dedicated to delivering innovative chip set solutions and system integration services, positioning itself as a key player in the RFID market.
HiScene
Series B in 2017
HiScene focuses on researching and developing core technologies and products for augmented reality. The company is committed to be an artificial intelligence company which provides the most natural human-computer interaction and explores the deepest data value.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.